Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database

Inclusion Criteria: * Participants in the advanced melanoma cohort * Participants included in the cohort by Flatiron criteria of: cutaneous melanoma with pathologic stages III or IV, either at initial diagnosis or via local or distant recurrence, and at least two clinic encounters evident in the database * Participants receiving Nivolumab + Relatlimab between March 18, 2022 and September 30, 2024 or other therapies (Nivolumab + Ipilimumab, immunotherapy monotherapy, BRAF/MEK inhibitors) between March 18, 2022 and November 30, 2024 (or date of the most recent data cut off) * Participants ≥18 years old on index date * Participants with ≥1 month of medical data after the index date (inclusive), unless patient died within this period Exclusion Criteria: * Participants with diagnosis of other primary cancers prior to the index date * Participants receiving medication in a clinical trial at any time prior to, on or after index date